Bayer today issued the following statement on the full defense verdict issued in the Johnson trial.
Bayer said today that, after careful and extensive consideration, it has decided not to file a petition for certiorari with the U.S. Supreme Court in the case of Dewayne Johnson v Monsanto, which will bring an end to this California state case.
On September 28, 2020, Monsanto filed a reply to the Plaintiff’s answer to the company’s Petition for Review with the California Supreme Court.
Amicus Letters Filed in California Supreme Court in Support of Monsanto’s Petition for Review of Johnson Case
Multiple amicus letters have been filed in support of Monsanto’s petition for review of the Johnson case before the California Supreme Court.
Monsanto filed a petition with the highest court in California seeking its review of the decision in Dewayne Johnson v. Monsanto Company, the first case in the Roundup™ litigation to go to trial. Monsanto asserts in the petition that the Court of Appeal’s recent decision warrants review because it conflicts with the law and longstanding legal principles with regard to federal preemption, design defect, failure to warn and punitive damages.
On December 6, 2019, the Court of Appeal of the State of California, First Appellate District – Division One, issued an order regarding an oral argument in the Johnson case. Read the order here.
The Recorder | By Amanda Bronstad
A California jury that awarded a $289 million Roundup verdict disregarded science and the consensus of federal regulators and fell victim to “emotional manipulation,” according to the state’s doctors, farmers and biotech firm Genentech Inc., in amicus briefs filed in Monsanto’s appeal.
Northern California Record | By Rich Peters
Four amicus briefs have been filed in the California Court of Appeals in the case of Dewayne Johnson v. Monsanto raising “concerns about the methods used to determine medical causation and the award of punitive damages in the Johnson case, as well as the reliance of businesses and consumers on regulatory approvals,” said a media representative for Bayer.